Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Memory Improvement With Docosahexaenoic Acid Study (MIDAS)
This study is ongoing, but not recruiting participants.
Sponsored by: Martek Biosciences Corporation
Information provided by: Martek Biosciences Corporation
ClinicalTrials.gov Identifier: NCT00278135
  Purpose

The purpose of this study is to investigate the effect of docosahexaenoic acid (DHA, 22:6n-3) in improving cognitive functions in subjects with age-related cognitive decline. DHA is a long chain omega-3 fatty acid (LC-PUFA) that plays an important role in neural and visual development and cardiovascular health.


Condition Intervention
Age-Related Cognitive Decline
Age-Related Memory Disorders
Dietary Supplement: DHA (nutritional supplement) or placebo

MedlinePlus related topics: Dietary Supplements Memory
Drug Information available for: Docosahexaenoic acids
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of DHA on Cognitive Functions in the Elderly

Further study details as provided by Martek Biosciences Corporation:

Primary Outcome Measures:
  • Determine the effects of DHA, a nutritional supplement (900 mg/d) on improving cognitive functions (i.e. working memory, memory retention, attention, and executive function) in healthy elderly subjects at 24 weeks [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Effects of DHA on visual acuity, levels of plasma phospholipids, and evaluating the safety and tolerability of the DHA dose administered [ Time Frame: 24 weeks ]
  • The study will include a screening period, baseline, and 24 week treatment period.

Estimated Enrollment: 465
Study Start Date: December 2005
Estimated Study Completion Date: December 2008
Arms Assigned Interventions
1: Active Comparator Dietary Supplement: DHA (nutritional supplement) or placebo
oral 900mg/day
2: Placebo Comparator Dietary Supplement: DHA (nutritional supplement) or placebo
oral 900mg/day

  Eligibility

Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females, aged 55 or greater.
  • Have a subjective memory complaint and have a Logical Memory subtest (of the Wechsler Memory Scale - III [WMS-III]) raw score one standard deviation or greater below the mean of a younger population.
  • Have the ability to understand the requirements of the study; be willing to provide written informed consent; and agree to abide by the study restrictions and return for the required assessments.
  • If taking non-prohibited medication, be on a stable drug regimen (in prior 3 months).

Exclusion Criteria:

  • Have a screening Mini-Mental State Examination (MMSE) < 26.
  • Consume greater than 200 mg/day DHA as assessed on a DHA Food Frequency Questionnaire in the prior 2 months to screening.
  • Use nutritional fish oil, flaxseed oil, omega-3 supplements, or huperzine in the prior 2 months to screening.
  • Use acetylcholinesterase inhibitors or memantine in the prior 2 months to screening.
  • Use major anti-psychotics or major anti-depressants.
  • Use lipase inhibitors such as Xenical® (orlistat).
  • History of major medical conditions including ischemic stroke, head trauma with loss of consciousness, epilepsy, psychosis, vascular dementia, depression (Geriatric Depression [15-item] > 5), myocardial infarction (within 1 year), uncontrolled diabetes, or blindness.
  • History of major surgery within the past 6 months.
  • Current use or history of drug and/or alcohol abuse within 5 years.
  • Administration of any investigational product within the past 30 days.
  • Inability to swallow capsules.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00278135

Locations
United States, Arizona
Pivotal Research Center
Mesa, Arizona, United States, 85210
United States, California
Pacific Research Network
San Diego, California, United States, 92103
Pacific Research Network
Vista, California, United States, 92083
United States, Colorado
Radiant Research Denver
Denver, Colorado, United States, 80212
United States, Florida
Brain Matters Research
Delray Beach, Florida, United States, 33445
Bradenton Neurology
Bradenton, Florida, United States, 34205
Stedman Clinical Trials
Tampa, Florida, United States, 33613
Meridien Research
St. Petersburg, Florida, United States, 33709
United States, Illinois
Radiant Research Chicago
Chicago, Illinois, United States, 60610
United States, Pennsylvania
Clinical Trial Center
Jenkintown, Pennsylvania, United States, 19046
United States, Texas
Senior Adults Specialty Research
Austin, Texas, United States, 78757
Radiant Research San Antonio
San Antonio, Texas, United States, 78229
United States, Utah
Radiant Research Salt Lake City
Salt Lake City, Utah, United States, 84107
United States, Vermont
Neurological Research Center, Inc.
Bennington, Vermont, United States, 05201
Sponsors and Collaborators
Martek Biosciences Corporation
Investigators
Study Director: Karin Yurko-Mauro, PhD Martek Biosciences Corporation
  More Information

Responsible Party: Martek Biosciences ( Karin Yurko-Mauro )
Study ID Numbers: 2005.1002
Study First Received: January 13, 2006
Last Updated: October 7, 2008
ClinicalTrials.gov Identifier: NCT00278135  
Health Authority: United States: Institutional Review Board

Keywords provided by Martek Biosciences Corporation:
Cognition
Memory
Nutrition
Omega-3
DHA

Study placed in the following topic categories:
Signs and Symptoms
Neurologic Manifestations
Neurobehavioral Manifestations
Memory Disorders

Additional relevant MeSH terms:
Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009